Silence breaks down phase 1 data on blood disorder prospect, sharing glimpse at pitch for competitive niche

Silence Therapeutics has spoken up about its phase 1 polycythemia vera (PV) clinical trial, providing an early look at how its siRNA prospect may match up to rivals from Incyte and Takeda.